Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
J. Clin. Oncol 2021 Feb 04;[EPub Ahead of Print], M Piccart, M Procter, D Fumagalli, E de Azambuja, E Clark, MS Ewer, E Restuccia, G Jerusalem, S Dent, L Reaby, H Bonnefoi, I Krop, TW Liu, T Pieńkowski, M Toi, N Wilcken, M Andersson, YH Im, LM Tseng, HJ Lueck, M Colleoni, E Monturus, M Sicoe, S Guillaume, J Bines, RD Gelber, G Viale, C ThomssenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.